vaccine efficacy

A ‘real-world’ study of vaccinated healthcare workers has found Covishield and Covaxin could produce a high immune response in up to 95% recipients and prevent serious disease in those infected after immunisation.

Chinese vaccines “don't have very high protection rates,” said the director of the China Centers for Disease Control. “It's now under formal consideration whether we should use different vaccines from different technical lines for the immunization process,” he said.

There have been cases in the country in which people tested positive for Covid-19, and even hospitalized, despite taking one or both doses of the Covid-19 vaccine. Several such cases were reported in Nagpur too. Now, Indian Council of Medical Research (ICMR) has decided to conduct a ‘real world’ study of vaccine efficacy to understand this phenomenon.

The efficacy of third doses of the Pfizer and Moderna mRNA vaccines wanes substantially by the fourth month after administration, a new study by the US Centers of Disease Control and Prevention (CDC) said Friday. Though it's now well documented that vaccine efficacy goes down after two doses, relatively little has been published on the duration of protection after a booster.

Punjab chief minister Captain Amarinder Singh on Friday directed the expert group headed by Dr Gagandeep Kang to start studying the effectiveness of vaccines in the context of the new variants of the coronavirus.

A leaked health ministry document has prompted calls in Thailand for medical staff inoculated against Covid-19 to be given a booster of an mRNA vaccine, after it included a comment that such a move could dent public confidence in Sinovac Biotech's vaccine. The internal memo, which included various opinions, was reported by local media and shared widely on social media.

Researchers at the Indian Institute of Science (IISc) here, and Queensland Brain Institute (QBI) in Australia have developed a mathematical model that predicts how antibodies generated by COVID-19 vaccines confer protection against symptomatic infections. The model can potentially optimise the use of available vaccines and speed up the development of new ones.

Scientists at the Indian Council of Medical Research-National Institute of Virology (ICMR-NIV) have initiated efforts to isolate and grow the Omicron strain of the novel coronavirus from the Dombivali man’s throat/nasal swab sample inside its high-end biosafety laboratory in Pune.

As Delhi government prepares to scale up the vaccination drive from this week, select centres are likely to see pre- and post-vaccination tests for “antibody titer”, which would help establish the efficacy of the Covid-19 vaccines and tackle vaccine hesitancy. The antibody titer test detects the presence and level of antibodies in the blood and helps gauge a person’s immune response.

India’s failure to quickly examine Covid-19 samples for new variants risks hurting its battle against a record surge of infections, with scientists warning the delays could damage everything from vaccine efficacy to effective hospital treatments.

United States biotech firm Moderna on Wednesday said it was pursuing regulatory approval for its Covid vaccine in children aged six months to six years after the two-shot regimen was found to be safe and produced a strong immune response.

Scientists at the Pune-based Indian Council of Medical Research-National Institute of Virology (ICMR-NIV) have successfully isolated the Omicron strain of the novel coronavirus at the high-end bio-safety laboratory in Pashan. The step is critical in assessing the efficacy of vaccine as well as natural infection-induced antibodies in thwarting severe disease.

Scientists at the Pune-based Indian Council of Medical Research-National Institute of Virology (ICMR-NIV) have successfully isolated the Omicron strain of the novel coronavirus. The exercise will also find an answer to another critical question: Will the new variant outsmart existing antibodies in those who have had Covid from old strains?

The Omicron coronavirus variant is more transmissible than the Delta strain and reduces vaccine efficacy but causes less severe symptoms according to early data, the World Health Organization said Sunday. The Delta variant, first identified in India earlier this year, is responsible for most of the world's coronavirus infections.

Researchers from Indian Institute of Science (IISc) and Queensland Brain Institute (QBI) in Australia have developed a mathematical model that predicts how antibodies generated by Covid-19 vaccines confer protection against symptomatic infections.